Clinical Trials Logo

Clinical Trial Summary

The purpose of this study was to allow continued use of nilotinib in patients who were on nilotinib treatment in a Novartis-sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study and were benefiting from the treatment as judged by the investigator


Clinical Trial Description

This was a multi-center, open label, single-arm, phase IV study to better characterize the long-term safety of nilotinib in patients treated in Novartis-sponsored studies and who benefited from treatment with nilotinib. Patients who were enrolled in Novartis-sponsored nilotinib studies, had benefitted from treatment with nilotinib and fulfilled all requirements in the parent study could be enrolled into the current roll-over study. There was no sample size estimation carried out for this study. Patients returned to the study center on a quarterly basis (12 weeks ± 1 week) for scheduled visit. Adverse Events (AEs) (non-serious and serious AEs), clinical benefit assessment by investigator and study medication dispensing information were collected. The original protocol of the current roll-over study was designed to provide continuation of treatment with nilotinib for patients enrolled in nilotinib studies. Therefore, the original protocol did not require AEs (non-serious and serious AEs) to be collected into the clinical database and only required serious adverse events (SAEs) to be collected in the Novartis safety database throughout the study duration. The scheduled visit frequency was annually. However, feedback from health authorities stated that all AEs should be collected. To account for this, the protocol was amended in 2016 (Protocol amendment 3 (PA 3)), with the primary objective changed to assess long-term safety of nilotinib. Consequently, PA 3 started to require all AEs (non-serious and serious AEs) to be entered into the clinical database, in addition to the continued SAE collection into the Novartis safety database. At the same time, the scheduled visit frequency was increased from annually to quarterly, and the protocol was also amended to require an investigator assessment of clinical benefit for patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01735955
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 4
Start date March 29, 2013
Completion date July 7, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT03590171 - International Study for Treatment of High Risk Childhood Relapsed ALL 2010 Phase 2
Terminated NCT02259348 - Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation Phase 2
Recruiting NCT01351545 - A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Recruiting NCT02894645 - Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study Phase 4
Completed NCT03236857 - A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies Phase 1
Completed NCT03181126 - A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma Phase 1
Recruiting NCT05291390 - Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT01758042 - Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders N/A
Completed NCT01221857 - Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies Phase 1/Phase 2
Completed NCT01282593 - Potential Role of CD9 and Implication of Motility Process in Pathogenesis of TEL/ALM1-positive ALL Relapses (LAL TEL/ALM1 and CD9). N/A
Completed NCT01885897 - IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT Phase 1/Phase 2
Completed NCT03067584 - Genetic Study of Familial Acute Lymphoblastic Leukemia
Recruiting NCT05884333 - Cord Blood Transplant in Adults With Blood Cancers Phase 2
Terminated NCT02338050 - Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation Phase 2
Completed NCT01802814 - International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 Phase 3
Completed NCT00495079 - Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia Phase 2
Terminated NCT01439347 - A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL Phase 3
Recruiting NCT04929899 - Bright Ideas - CIN Feasibility Study N/A
Active, not recruiting NCT02061800 - CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant Phase 1/Phase 2
Terminated NCT01050764 - Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells Phase 1/Phase 2